New York, USA, May 02, 2023 (GLOBE NEWSWIRE) — Acute Heart Failure Market to Witness Upsurge in Growth, Examine DelveInsight | Key Companies in the Domain – AstraZeneca, Boehringer Ingelheim, Eli Lilly and Company, Idorsia, Bristol-Myers Squibb, Novartis, Trevena, Scios
The acute heart failure market dynamics are expected to change in 7MM in the coming years owing to the increasing research and development strategies, rising prevalence of the disease, increasing evidence-based therapies, growing aging of the population, and others.
DelveInsight’s Acute Heart Failure Market Insights report includes a comprehensive understanding of current treatment practices, acute heart failure emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Acute Heart Failure Market Report
- As per DelveInsight analysis, the acute heart failure market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- DelveInsight’s analysis shows that acute heart failure cases show an increasing trend in the forecasted period in the 7MM.
- Leading acute heart failure companies such as Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others are developing novel acute heart failure drugs that can be available in the acute heart failure market in the coming years.
- Some of the key therapies for acute heart failure treatment include APD418, Dapagliflozin, PL-3994, Empagliflozin, COMPASSION Digital Biomarker, Relaxin, RLX030, Tezosentan, Clevidipine, CXL-1427, CD-NP, TRV027, BMS-986231, Nesiritide, LCZ696, and others.
- Several acute heart failure therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major acute heart failure market share @ Acute Heart Failure Market Report
Acute Heart Failure Overview
Heart failure is also known as congestive heart failure. It is also classified as left-side heart failure and right-side heart failure. The word corpulmonale refers to right-side heart failure caused by elevated blood pressure in the pulmonary arteries and right ventricle. There are two types of heart failure: acute and chronic. Acute heart failure has a fast onset and symptoms might occur without notice. However, with chronic heart failure, this challenge is continuing and long-term. It was shown that the majority of patients suffer from chronic heart failure.
Acute heart failure is a syndrome characterized as the beginning or worsening of heart failure symptoms and signs, most of which are associated to systemic congestion. Acute heart failure is characterized clinically by symptoms and signs related to systemic congestion. Shortness of breath while moving or resting flat, also known as dyspnea, fatigue, swelling of the feet, ankles, legs, belly, or veins in the neck, are all acute heart failure symptoms. To diagnose acute heart failure patients, healthcare personnel conduct a fast assessment that includes the patient’s health history and a physical exam to learn about the symptoms of acute heart failure patients.
Acute Heart Failure Epidemiology Segmentation
The acute heart failure epidemiology section provides insights into the historical and current acute heart failure patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
The acute heart failure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Acute Heart Failure Prevalent Population
- Acute Heart Failure Diagnosed Prevalent Population
- Acute Heart Failure Gender-specific Diagnosed Prevalent Cases
- Acute Heart Failure Age-specific Diagnosed Prevalent Cases
Download the report to understand which factors are driving acute heart failure epidemiology trends @ Acute Heart Failure Epidemiological Insights
Acute Heart Failure Treatment Market
Acute heart failure can be fatal; therefore, anyone experiencing symptoms should seek medical attention as soon as possible. Acute heart failure treatment focuses first on life-threatening symptoms, then on determining underlying causes and treating lingering symptoms. While heart performance improves, hospitalization is usually required. There are several possible treatments for acute heart failure. The treatment chosen will be determined by the person’s symptoms and the underlying issue that is producing them. As an example, Dyspnea: Supplemental oxygen is used to address this condition. The severity of dyspnea will determine whether oxygen is delivered through a nasal tube or a face mask. Sitting up straight can aid in breathing. Fluid buildup: Intravenous diuretics are used to treat fluid buildup within the body. Diuretics, as well as oxygen and heart failure medicines, will be used to treat pulmonary edema.
The majority of people with acute heart failure have deteriorating chronic heart failure symptoms. Once the acute episode has been stabilized, various medications might be provided. The majority of these are vasodilators, which assist reduce blood pressure by widening blood vessels: Angiotensin-converting enzyme (ACE) inhibitors, which lower blood pressure and heart stress, Hydralazine, isosorbide, and angiotensin receptor blockers (ARB) are all blood pressure medications that operate by relaxing blood arteries. Aldosterone antagonists, which lower blood pressure by lowering sodium levels in the body; Beta blockers are medications that reduce blood pressure and slow the heart rate. Digoxin, which causes the heart to beat faster, Nitrates, which are typically used as a vasodilator when the patient also has pulmonary edoema, Pain relievers, such as morphine, may be beneficial in reducing anxiety in persons who are agitated and upset.
To know more about acute heart failure treatment, visit @ Acute Heart Failure Treatment Drugs
Key Acute Heart Failure Therapies and Companies
- APD418: Arena Pharmaceuticals
- Dapagliflozin: AstraZeneca
- PL-3994: Palatin Technologies, Inc
- Empagliflozin: Boehringer Ingelheim/Eli Lilly and Company
- COMPASSION Digital Biomarker: Aventyn, Inc.
- Relaxin: Corthera, Inc
- RLX030: Novartis
- Tezosentan: Idorsia Pharmaceuticals Ltd.
- Clevidipine: The Medicines Company
- CXL-1427: Bristol-Myers Squibb/Cardioxyl Pharmaceuticals, Inc
- CD-NP: Nile Therapeutics
- TRV027: Trevena Inc.
- BMS-986231: Bristol-Myers Squibb
- Nesiritide: Scios, Inc.
- LCZ696: Novartis
Learn more about the FDA-approved drugs for acute heart failure @ Drugs for Acute Heart Failure Treatment
The acute heart failure market is expected to change in the coming years. The rising healthcare spending across the globe is propelling the growth of the acute heart failure market. Moreover, the acute heart failure pipeline is highly robust; many possible therapies are being studied for acute heart failure treatment, and it is safe to assume that the therapeutic space will substantially impact the acute heart failure market throughout the forecast period. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate are likely to boost the growth of the acute heart failure market in the 7MM.
However, certain factors may affect the growth of the acute heart failure market. The acute heart failure market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the acute heart failure market growth. Moreover, there are several generics, and off-label therapies that are available in the market for the treatment of patients affected by heart failure posing a threat to the acute heart failure market.
|Coverage||7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]|
|Key Acute Heart Failure Companies||Arena Pharmaceuticals, AstraZeneca, Palatin Technologies, Inc, Boehringer Ingelheim, Eli Lilly and Company, Aventyn, Inc., Corthera, Inc, Idorsia Pharmaceuticals Ltd., The Medicines Company, Bristol-Myers Squibb, Cardioxyl Pharmaceuticals, Inc, Nile Therapeutics, Trevena Inc., Scios, Inc., Novartis, and others|
|Key Acute Heart Failure Therapies||APD418, Dapagliflozin, PL-3994, Empagliflozin, COMPASSION Digital Biomarker, Relaxin, RLX030, Tezosentan, Clevidipine, CXL-1427, CD-NP, TRV027, BMS-986231, Nesiritide, LCZ696, and others|
Scope of the Acute Heart Failure Market Report
- Therapeutic Assessment: Acute Heart Failure current marketed and emerging therapies
- Acute Heart Failure Market Dynamics: Attribute Analysis of Emerging Acute Heart Failure Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Acute Heart Failure Market Access and Reimbursement
Discover more about acute heart failure drugs in development @ Acute Heart Failure Clinical Trials
Table of Contents
|1.||Acute Heart Failure Market Key Insights|
|2.||Acute Heart Failure Market Report Introduction|
|3.||Acute Heart Failure Market Overview at a Glance|
|4.||Acute Heart Failure Market Executive Summary|
|5.||Disease Background and Overview|
|6.||Acute Heart Failure Treatment and Management|
|7.||Acute Heart Failure Epidemiology and Patient Population|
|9.||Acute Heart Failure Marketed Drugs|
|10.||Acute Heart Failure Emerging Drugs|
|11.||Seven Major Acute Heart Failure Market Analysis|
|12.||Acute Heart Failure Market Outlook|
|13.||Potential of Current and Emerging Therapies|
Acute Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute heart failure companies, including Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, among others.
Acute Heart Failure Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted Acute Heart Failure epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Heart Failure Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key heart failure companies, including Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, among others.
Advanced Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced heart failure companies, including Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, among others.
Chronic Heart Failure Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic heart failure companies, including Zensun (Shanghai) Sci & Tech, Cytokinetics, Mesoblast, Shanghai Hongyitang Biopharmaceutical Technology, Tasly Pharmaceuticals, among others.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Acute Heart Failure Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Blogs
Related Healthcare Services
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us Shruti Thakur [email protected] +1(919)321-6187 www.delveinsight.com